Health Canada

In Canada, common allergens and gluten sources must always be clearly declared on food labels when present as ingredients or components of ingredients. They will appear in the ingredient list or in a “Contains” statement located immediately after the ingredient list.

It is estimated that between 1.8 and 2.1 million Canadians may be affected by food allergies.

Health Canada is proposing to introduce mandatory front-of-package (FOP) labelling requirements for foods high in nutrients of public health concern - sodium, sugars and saturated fat - due to excessive intakes.

Food from foodservice establishments is often high in sodium. Excess sodium intake can increase the risk of high blood pressure, stroke, and chronic diseases such as heart or kidney disease.

Health Canada is proposing to prohibit the use of partially hydrogenated oils (PHOs), the main source of industrially produced trans fatty acids (trans fats), in foods sold in Canada.

Healthy eating is more than the foods you eat. It is also about where, when, why and how you eat.

Regulatory Initiative: Amendments to the Food and Drug Regulations - Nutrition Labelling - Forward Regulatory Plan 2015-2017

Regulatory Initiative: Amendments to the Food and Drug Regulations Division 15 and 16 Clean Up for Food Additives - Forward Regulatory Plan 2015-2017

As part of the Healthy Eating Strategy, Health Canada is proposing to restrict the marketing of unhealthy food and beverages to children.

Health Canada develops food safety and nutritional regulations, policies and guidance under the Food and Drugs Act. This act governs the safety and nutritional quality of food sold in Canada.

It presents the Patent Act Schedules #1, #2, #3 and #4.

Canada's Access to Medicines Regime is intended to address public health problems afflicting many developing and least-developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria and other diseases.

Canada's Access to Medicines Regime provides a framework within which eligible countries can import less expensive generic versions of patented drugs and medical devices.

This document provides guidance on the study and analysis of sex differences in clinical trials of therapeutic products in order to generate evidence to advise on the optimal use of therapeutic products in both women and men.

The purpose of this guidance document is to give drug and medical device manufacturers instructions on how to prepare clinical information documents for release and give members of the public instructions on how to request this information.

It presents WTO-Member Countries Eligible to Import Under the Regime

Governments can override patent rights when necessary. In such instances, the government authorizes a third party to use the patented invention without the patent holder's permission. This authorization comes in the form of a compulsory licence.

Countries with insufficient or no manufacturing capacity in the pharmaceutical sector can benefit from participating in Canada's Access to Medicines Regime. Under the Regime, eligible countries can import less expensive, generic versions of patented products manufactured in Canada.

We are working to make clinical information about the safety and efficacy of drugs and medical devices available to the public. Information that Health Canada currently treats as confidential would be made publicly available following a final regulatory decision.

For the purpose of this guidance document, Health Canada has determined that certain submissions and applications involving human or disinfectants drugs may be submitted for administrative processing as they do not contain scientific data.